Search Results

You are looking at 121 - 130 of 2,671 items for :

  • Refine by Access: All x
Clear All
Full access

Cari Utendorf, Amy Compston, and Brittany Knauss

intervention to prevent further functional decline throughout cancer treatment. Methods : Physical therapy (PT) is integrated in the cancer-aging resiliency and pancreatic clinics. A PT evaluation is completed, with the following outcomes obtained as listed in

Full access

Rahul Aggarwal, Tian Zhang, Eric J. Small, and Andrew J. Armstrong

and outcomes of NEPC Outline treatment options for patients with NEPC Neuroendocrine prostate cancer (NEPC) is a lethal form of prostate cancer, with most patients dying within 1 to 2 years of diagnosis. 1 , 2 Pure localized small cell carcinoma

Full access

David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner, and Henry S. Friedman

associated with poor outcome among patients with glioblastoma. 30 , 31 VEGF-A isoforms generated by alternative splicing can also originate from host sources, such as invading macrophages and platelets, whereas tumor stroma can sequester larger isoforms that

Full access

Ajeet Gajra, Alissa S. Marr, and Apar Kishor Ganti

patient populations that respond differently to treatment and have different outcomes. 7 Another challenge in interpreting the trial evidence for this group of patients is the subjectivity associated with assigning a PS to any given patient. A recent

Full access

Philippe E. Spiess

NCCN Panel on bladder and penile cancers. With the use of non–evidence-based treatment approaches, outcomes can widely vary. To clarify some of the controversies associated with the treatment of penile cancer, NCCN has created inaugural NCCN Clinical

Full access

Justine M. Kahn and Melissa Beauchemin

, adolescents, and young adults (AYA; aged 15–39 years) with HL exceed 95%, with event-free survival (EFS) rates >85%. 4 The treatment successes in HL are attributed, in part, to 4 key factors: (1) research to identify disease-related predictors of poor outcome

Full access

Sherif R. Z. Abdel-Misih, Lai Wei, Al B. Benson III, Steven Cohen, Lily Lai, John Skibber, Neal Wilkinson, Martin Weiser, Deborah Schrag, and Tanios Bekaii-Saab

Background Nodal status has long been considered a key pathologic factor in cancer management and care. Previous studies have demonstrated an association between lymph node yield and status with regard to patient outcomes in colorectal cancer

Full access

Joseph C. Alvarnas and Patrick A. Brown

Outcomes for patients with acute lymphoblastic leukemia (ALL) have improved dramatically over the past 4 decades. Overall 5-year relative survival rates for patients with ALL have increased from 40.6% during the period between 1975 and 1977 to 70

Full access

Doris Howell, Gregory R. Pond, Denise Bryant-Lukosius, Melanie Powis, Patrick T. McGowan, Tutsirai Makuwaza, Vishal Kukreti, Sara Rask, Saidah Hack, and Monika K. Krzyzanowska

also examined preliminary estimates of effectiveness based on patient-reported outcomes. Methods Participants and Recruitment Procedures Ethics approval was obtained from the Ontario Cancer Research Ethics Board for all participating sites

Full access

Jad Chahoud, Adele Semaan, and Alyssa Rieber

Background The health care system in the United States is characterized by an unsustainable increase in spending with penultimate outcomes. 1 , 2 In 2013, the United States spent a total of $2.9 trillion on health, which is approximately $9